TICKERNERD
Menu
ELUTELUTHealthcare · Medical Devices

ELUT Stock Forecast: Elutia, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$0.83
+0.89% on the day

The 1 Wall Street analysts covering Elutia, Inc. hold a median 12-month price target of $5 — +504.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$36.3M
Ticker Nerd rank
29 / 100
Median analyst target
$5.00
Analysts covering
1
Revenue$2.4M−61.2% y/y
Operating income−$5.9M
Net income−$7.6M
Free cash flow−$8.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.4%
1M
−0.3%
YTD
+19.4%
1Y
−6.9%
From 52W high
−32.2%
From 52W low
+63.8%
$0.51
$1.22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ELUT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Elutia, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
29 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
84
Issuance
75
Growth
61
Quality
37
Volatility
35
Revisions
32
Momentum
26
Value
20
Accruals
14

Size (84): Smaller than most of the companies we track.

Accruals (14): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ELUT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ELUT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00Jan 26Apr 26Jul 26Oct 26ELUTHigh $5.00Median $5.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $5.00Median $5.00High $5.00

The green dot is the last close — the median target sits +504.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
10 Sept 2025Lake StreetMaintainsBuy$8.00 → $6.00
10 Sept 2025Lake StreetMaintainsBuy—
9 May 2025Lake StreetMaintainsBuy—
7 Mar 2025Cantor FitzgeraldReiteratesOverweight—
15 Nov 2024Cantor FitzgeraldReiteratesOverweight—
6 Sept 2024Cantor FitzgeraldReiteratesOverweight—
8 Aug 2024Cantor FitzgeraldMaintainsOverweight—
21 June 2024Lake StreetMaintainsBuy—
20 June 2024Cantor FitzgeraldMaintainsOverweight—
18 June 2024Cantor FitzgeraldMaintainsOverweight—
10 May 2024Cantor FitzgeraldMaintainsOverweight—
14 Nov 2023Cantor FitzgeraldMaintainsOverweight—
28 Sept 2023Lake StreetInitiatesBuy—
26 Sept 2023Cantor FitzgeraldReiteratesOverweight—
19 Sept 2023Cantor FitzgeraldReiteratesOverweight—
15 Aug 2023Cantor FitzgeraldReiteratesOverweight—
12 May 2023Cantor FitzgeraldMaintainsOverweight$12 → $10
16 Nov 2022Truist SecuritiesMaintainsBuy$8.00 → $10
15 Nov 2022Piper SandlerMaintainsOverweight$9.00 → $11
4 Mar 2022Cowen & Co.MaintainsOutperform$15 → $13

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ELUT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ELUT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Elutia, Inc. returned −6.9% against +16.2% for the S&P 500, dividends included.

ELUT vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Jan 26Apr 26Jul 26Oct 26ELUTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ELUT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Elutia, Inc. (ELUT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.6×

Cheaper than 71% of US stocks

Price / sales
3.0×

Cheaper than 40% of US stocks

Price / book
2.3×

Cheaper than 39% of US stocks

EV / EBITDA
−1.0×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
−11.6%

Higher than 15% of US stocks

Earnings growth (YoY)
−61.2%

Higher than 8% of US stocks

Gross margin
59.6%

Higher than 73% of US stocks

Operating margin
−243.1%

Higher than 10% of US stocks

Net margin
426.9%

Higher than 99% of US stocks

Returns & dividend
Return on equity
192.9%

Higher than 98% of US stocks

Return on assets
−34.7%

Higher than 12% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Elutia, Inc. (ELUT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Elutia, Inc. has a market value of $36.3M and an enterprise value of $20.8M.

  • Revenue in the twelve months to 30 June 2026: $12.1M. The latest quarter shrank 11.6% year on year.

  • Net income over the same four quarters: $51.8M, a 426.9% net margin.

  • Diluted earnings per share, trailing twelve months: $0.95.

  • Free cash flow in the twelve months to 30 June 2026: −$46.0M, after $2.0M of capital spending.

  • Shares outstanding: 44.3M.

  • Trailing P/E: 0.6×; forward P/E: −0.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Elutia, Inc. employs 25 people — $485K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

ELUT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
ELUTElutia, Inc.$36.3M
29
QTIQT Imaging Holdings, Inc.$38.1M
21
NSYSNortech Systems, Inc.$31.5M
81
RPIDRapid Micro Biosystems, Inc.$42.9M
24
CVRXCVRx, Inc.$44.2M
29
NNOXNano-X Imaging Ltd.$44.5M
18
XTNTXtant Medical Holdings, Inc.$45.0M
74

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Elutia, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ELUT news & analysis

Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029

GlobeNewsWire · 1 Oct 2026positive

Elutia announced it has received the full $8 million held in escrow from Boston Scientific in connection with the sale of its BioEnvelope business, released on schedule with no claims. This escrow release marks the third funding catalyst for Elutia in 2026, following its Avenue Capital loan facility and the SimpliDerm divestiture, leaving the company fully funded into 2029 and through the first year of the expected NXT-41x launch.

Why it matters — The escrow release provides additional capital that fully funds Elutia into 2029, removing near-term funding pressure as it prepares for the expected NXT-41x launch.

Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th

GlobeNewsWire · 10 Sept 2026neutral

Elutia announced that its CEO, Chief Scientific Officer, and CFO will present and host one-on-one meetings with investors at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th. The company described itself as a pioneer in drug-eluting biomatrix technologies.

Why it matters — The conference appearance gives ELUT watchers an opportunity to hear directly from the company's leadership about its drug-eluting biomatrix technologies and engage with top executives.

Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 2 Sept 2026neutral

Elutia announced that its CEO Dr. Randy Mills, CFO Matthew Ferguson, and CSO Dr. Michelle Williams will participate in two upcoming investor conferences: the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference and the H.C. Wainwright 28th Annual Global Investment Conference.

Why it matters — An ELUT watcher would care because Elutia's leadership team is scheduled to present at these investor conferences, raising the company's visibility among institutional investors.

Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.

GlobeNewsWire · 18 Aug 2026neutral

Cellution Biologics announced it has completed its acquisition of the SimpliDerm hydrated human acellular dermal matrix (ADM) business from Elutia Inc. The transaction was announced in a GlobeNewsWire release dated August 18, 2026.

Why it matters — The completion of this divestiture marks a structural change in Elutia's business, as it has transferred ownership of its SimpliDerm ADM product line to Cellution Biologics.

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

GlobeNewsWire · 18 Aug 2026positive

Elutia completed the sale of its SimpliDerm human acellular dermal matrix business to Cellution Biologics, receiving $8 million in cash at closing with up to $3 million in additional milestone payments over 18 months. The divestiture focuses Elutia's resources on developing and commercializing its NXT-41x antibiotic-eluting biomatrix, with clearance expected in the first half of 2027.

Why it matters — This divestiture adds cash to Elutia's balance sheet and concentrates the company's resources on advancing NXT-41x toward commercial launch.

FAQ

Frequently asked questions about ELUT stock

What is the ELUT stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Elutia, Inc. have a median 12-month price target of $5, with estimates ranging from $5 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ELUT stock a buy right now?

Of the 1 analysts covering Elutia, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Elutia, Inc. 29 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ELUT?

As at 8 Oct 2026, Elutia, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (84 of 100).

Will ELUT stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +504.4% from the last close, and Ticker Nerd's factor model ranks Elutia, Inc. 29 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ELUT stock forecast for 2030?

No analyst covering Elutia, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELUT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $5 over the next 12 months.

How has ELUT stock performed over the past year?

Elutia, Inc. returned -6.9% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Elutia, Inc. do?

Elutia Inc. is a commercial-stage biomedical company focused on drug-eluting biomatrix products used in surgical reconstruction and related medical applications.

What is the latest news on ELUT?

The most recent item we track (GlobeNewsWire, 1 Oct 2026): "Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029". Elutia announced it has received the full $8 million held in escrow from Boston Scientific in connection with the sale of its BioEnvelope business, released on schedule with no claims. This escrow release marks the third funding catalyst for Elutia in 2026, following its Avenue Capital loan facility and the SimpliDerm divestiture, leaving the company fully funded into 2029 and through the first year of the expected NXT-41x launch.

Company

About Elutia, Inc.

Elutia Inc. is a commercial-stage biomedical company focused on drug-eluting biomatrix products used in surgical reconstruction and related medical applications. Elutia’s products are designed to improve how implantable medical devices and surrounding tissue interact, with use cases in areas such as device protection, women’s health, and cardiovascular care. The company offers biologic solutions intended for procedures involving implanted electronic devices, soft tissue repair, and regenerative support. Its portfolio serves healthcare providers working across specialized surgical settings where compatibility, tissue integration, and complication reduction are important. Elutia Inc. operates as a focused player in the regenerative medicine and biomaterials market, addressing needs in implant-based procedures and reconstructive care.

CEO Dr. C. Randal Mills Ph.D. · 25 employees · United States · https://elutia.com